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Artificial intelligence can improve decisionmaking in infection management
Antibiotic resistance is an emerging global danger. Reaching responsible prescribing decisions requires the integration of broad and complex information. Artificial intelligence tools could support decision-making at multiple levels, but building them needs a transparent co-development approach to ensure their adoption upon implementation.
Timothy M. Rawson, Raheelah Ahmad, Christofer Toumazou, Pantelis Georgiou and Alison H. Holmes O ptimal decision-making in healthcare is commonly influenced by the boundary of rationality 1 . As described by Simon, this concept proposes that irrespective of a decision-maker's intelligence, their decision making will often be limited by three unavoidable constraints: (i) information available to make decisions is often limited and potentially unreliable; (ii) the human mind has a limited capacity; and (iii) there is only a limited amount of time in which to make a decision 1 . Therefore, in complex situations an individual will often pursue a course of action that satisfies the minimal requirements necessary to achieve a particular goal rather than an optimal choice, even when attempting to be rational in their decision making.
Artificial intelligence (AI) is the use of computer algorithms to mimic human cognitive functions such as learning or problem solving. AI facilitates the analysis of data with a lens that surpasses human capacity through its ability to process data and information, addressing the issue of 'bounded rationality' . AI is also devoid of behavioural limitations, including unsubstantiated deviation from evidence based guidelines, influence of peers in hierarchical cultural norms, and fatigue 2 . The computer can learn in an objective manner, providing predictions that are often more accurate than observed in routine practice 3 . In the last 20 years the concept of AI has grown exponentially, as evidenced in published works: there was a more than six-fold increase in AI-related publications registered in PubMed.gov in the past two decades. It's necessary to learn from early applications of AI and assess the potential for its future impact to address some of the immediate challenges in healthcare. In particular, how can AI help in situations when the concept of the rational choice has the additional complexity of considering long-term individual and societal harm as well as individual benefit in the short term? As an example, this article will explore the role of AI to support optimal antibiotic decision-making.
AI to optimise antibiotic prescribing
Antibiotic prescribing, whether appropriate or inappropriate, is a driver of antimicrobial resistance 4 . Antimicrobial resistance is a complex social and biological challenge that reflects many of the problems Simon set out when describing the boundary of rationality 1, 5 . It is also an ideal example of when caring for an individual has immediate and far reaching externalities. A decision made to prescribe an antibiotic affects not only the individual patient, but also individual's microbiome and society as a whole, through the selection of drugresistant organisms. Decision making during infection management is a dynamic and often inconsistent process 5 . There is often a paucity of evidence to support antibiotic prescribing, with heterogeneous, proxy outcome measures used as gold standards. Concerns over high mortality associated with delays in prescribing in conditions such as sepsis, the increasing rate of drug-resistant infections, and lack of robust diagnostics to support dynamic decision-making lead clinicians to overuse antibiotics. This overuse of antibiotics is therefore observed even when there is low likelihood of infection being present and is further demonstrated across different healthcare settings through data on medication errors and the prevalence of healthcare associated infections.
In an attempt to optimise treatment, reduce the inappropriate use of antibiotics, and promote more balanced, socially considerate prescribing, interventions have been put in place to support evidence-based decision-making. These interventions, Credit: Islandstock / Alamy Stock Photo comment collectively referred to as antimicrobial stewardship, ultimately are an effort toward behavioural change at the individual and organisational level. Investment in the field has focused on the development of diagnostics to help augment antimicrobial stewardship, but such developments have been piecemeal and isolated from the systems within which they should be embedded to impact behaviour 4, 5 . AI provides the potential to integrate these complex processes and support optimal use of data for evidence-based decision-making.
Factors influencing nonadoption
The development of electronic clinical decision systems to support antibiotic prescribing have been widely explored 6 . These are computerised programmes that are designed to help healthcare professionals or patients make decisions about healthcare. In other fields, clinical decision support systems (CDSS) have improved the quality and safety of healthcare decisions 7 . But many of the CDSS focused on antimicrobial stewardship, and more widely in healthcare, are yet to be successfully adopted. Whilst many factors have been cited for adoption failures, it appears largely due to a late consideration of co-design and of the behavioural factors that govern their use 6, 7 . This often leads to the implementation of adynamic systems that lack the flexibility required to seamlessly integrate into practice. A further challenge in the field of infection is the requirement to focus decision support not only on human factors, but also on those of the pathogen, the antibiotic being prescribed in the context of individual polypharmacy, the evolution of resistance, the symbiotic microbiome, and the wider environment.
Future development of AI systems
The global increase in electronic health record utilisation has generated large amounts of routinely available electronic patient and microbiological data that could be utilised to support individualised antimicrobial stewardship. While this access opens up opportunities for advancing applications, the sheer volume of data available will present challenges to identify the most useful information and filter out noise. Training AI to perform data-cleaning functions and to deal with missing data are exciting opportunities. The parallel advances in computer processing capabilities and AI algorithms also present the potential to develop tools for prediction. In the field of infection, AI may enhance our ability to make individualised treatment decisions, even when there is a limited evidence base, whilst also monitoring for unintended consequences of decisions. However, lessons must be learnt from the current difficulties with promoting adoption of clinical decision support tools.
The development of AI systems in the field of infection is still in its infancy. A range of supervised and unsupervised AI tools have been developed, including causal probabilistic networks and support vector machine classifiers. 6, 8 These tools have shown high accuracy in predicting infection and recommending appropriate antibiotic therapy 6, 8 . For example, Leibovici and colleagues reported a cluster-randomised control trial of a decision-support tool containing a causal probabilistic network that improved the appropriateness of antibiotic prescribing significantly 8 . Whilst these tools have the potential, a number of barriers remain to their adoption. These can be classified at the micro (individual health professional) and macro (health system and beyond) levels of healthcare systems. A common concern with current AI systems is the widespread, unregulated training of these systems during their development; as well as the unsupervised nature of learning upon implementation. Insufficient attention to the human-computer interface as part of clinical decision support at the design phase means systems are ergonomically weak.
At the macro level, there is currently very little guidance or regulation governing the training and development of artificial intelligence systems. Dataset size, generalizability of training sets, and evaluation of systems before deployment are often left to the discretion of the developer, with safety and translatability to other clinical situations often unclear. This lack of regulation has led to concerns about adoption of such tools, providing a major barrier to successful implementation. At the micro level, the unsupervised nature with which systems can then continue to learn and develop means that errors input into the system may be propagated and go unnoticed unless supervised, leading to patient and/or societal harm. Currently, there is little thought put into how these potential unintended consequences of artificial intelligence will be monitored for and how systems will respond to them when they are identified.
Current media attention around the use of artificial intelligence has attracted some strong opinions in terms of safety in healthcare. For example, the claims made by Babylon Healthcare that their chatbot was able to make diagnoses at a similar level to primary care physicians in the UK 9 has led to a mixed response from healthcare professionals and the public. As well as concerns over the accuracy claimed by the company, the system has also had a significant impact financially, increasing acute medical activity in the area it was deployed 9 . From the patient perspective, confidence in computer-driven decisions regarding healthcare is mixed. In a recent study exploring public confidence in computer-driven decisions, citizens reported that whilst computer-supported decisionmaking had potential benefits in improving accuracy, interaction and oversight from a medical professional remained important 10 . This was reported by participants to be based on the realisation that human interaction cannot simply be based on evidence, but must also take the social and cultural context in which the decision is made into account. For antibiotic prescribing, many potential end-users are currently uncomfortable about the way that decision support will be implemented, especially when the system may tend towards a more societal perspective than that of the individual, as is often the case when decisions are made for infection management.
Many of these barriers can be addressed through the engagement of healthcare professionals, patients, and carers early in the development of such tools. AI development emphasizes participatory approaches because, in essence, it aims to simulate capacities of human intelligence. However, while co-design of the system to improve design and the functionality aspects are important, it may not be enough. Co-design must also alleviate concerns and help to promote greater transparency in how the recommendations being made by the system have been developed and are utilised to augment human decision-making. This will promote better understanding of the role of these tools in healthcare and help foster the realisation that, although human subjectivity can be removed from prediction, it cannot be removed from the practice of evidence based medicine. This is because the individual, social, and microbiological context in which a decision is made requires the human decision-maker.
Building AI-integrated systems
It is clear that understanding the data sources that inform AI and understanding how ecological and epidemiological environments incorporate are of critical importance. A recent illustration of this, by Chen and colleagues 2 , found that when predicting readmission to hospital, the social determinants of health, often dismissed as small variations by predictive tools, could in fact accumulate to have a significant impact on future events for individual patients 2 .
Examples like this demonstrate that whilst AI will undoubtedly enhance our ability comment to support decision making in healthcare, humanisation of outputs is still required to contextualise information to the individual.
Decades of learning from innovation adoption and individual and organisational behavioural research demonstrate that co-design of systems can not only promote better adoption of interventions but also support transparency in the technical infrastructure that makes up AI platforms used in medicine. This appropriately challenges AI experts to be able to explain and engage with the end user, not just in terms of optimal design of the tool and features, but also about the infrastructure and training of the AI system and its potential unintended consequences of use in a way that is comprehensible to all. This will have the further benefit of promoting expert engagement in the development and shaping of systems to ensure that AI is individually, locally, and contextually relevant whilst remaining sensitive to emerging global epidemiology.
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